|
|
5-day change | 1st Jan Change | ||
|
92.00 DKK |
+0.38% | +5.75% | +4.43% | |
Published on 11/16/2026
at 06:05 am EST
Publicnow
TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM
16.11.2026 11:59:02 CET | Ambu A/S | Changes in company’s own shares
On 5 November 2026, Ambu announced a share buyback program (company announcement no. 3 2026/27). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.
During the program, Ambu will repurchase shares for a total amount of up to DKK 400m from 9 November 2026 until no later than 30 April 2027. The repurchased shares are bought with the purpose of reducing the share capital in accordance with Article 5(2)(a) in MAR.
The following transactions have been made under the program from 9 November 2026 to 13 November 2026:
|
Number of shares |
|
|
|
|
|
|
|
|
|
|
45,000 |
88.2600 |
3,971,700 |
|
2026.11.10 |
45,000 |
86.8600 |
3,908,700 |
|
2026.11.11 |
45,000 |
86.8500 |
3,908,250 |
|
2026.11.12 |
43,000 |
87.5000 |
3,762,500 |
|
2026.11.13 |
38,000 |
90.1100 |
3,424,180 |
|
Accumulated under the program |
|
|
|
Following the transactions disclosed above, the remaining amount available under the program is DKK 381,024,670. Ambu now owns 8,857,687 treasury shares, corresponding to 3.3% of the share capital.
Contacts
- Lisa Bedell Clive, Head of Investor Relations, +44 7385 420133, licl@ambu.com
- Tine Bjørn Schmidt, Director of Global Brand & Communications, +45 2264 0697, tisc@ambu.com
About Ambu A/S
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.
Download announcement as PDF.pdf https://attachment.news.eu.nasdaq.com/a87ab359d8489b1afd521147c4701785d
Company News Subscribe European Market Activity Nasdaq Europe
© 2026, Nasdaq, Inc. All Rights Reserved.
Attachments
- Original document
- Permalink
Disclaimer
Ambu A/S published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 11:04 UTC.
Ambu A/S is specialized in the design, production and marketing of medical supplies. Net sales break down by family of products as follows:
– emergency care and resuscitation devices (50.8%): mechanical ventilation devices (insufflators, laryngeal masks, facial masks and respiratory bags), secretion aspirators, immobilization devices, etc. In addition, the group sells dummies for first aid training centers;
– single-use endoscopes (30.2%);
– monitoring and diagnostic devices (19%): including electrodes used in the fields of cardiology, neurophysiology and first aid.
At the end of September 2025, Ambu A/S had four production sites located in China, Malaysia, the United States and Mexico.
Net sales are distributed geographically as follows: Denmark (1%), Europe (38.9%), the United States (49.3%), North America (1.2%) and other (9.6%).
Buy
Average target price
95.04DKK
Spread / Average Target
+3.70%
Select your edition
All financial news and data tailored to specific country editions